The UAB Department of Psychiatry and Behavioral Neurobiology conducts clinical trials of novel and established treatments.
These trials examine mechanisms of action, safety and efficacy profiles, as well as the pathophysiology of the condition being studied. This work is translational by nature because all three phases of human testing are the essential steps before new agents can be used in clinical practice. Our work often focuses on treatments targeting the most treatment-resistant forms of mental illness. This work is vital, as many current treatments in psychiatry do not target the underlying causes of disease and leave many patients without an adequate response. In addition to targeting treatment resistance, some studies aim to modify the disease course, especially treatments designed to alter it as soon as possible after symptoms develop.
Our expertise covers both common and less common mental disorders, including mood and psychotic disorders, substance use disorders, anxiety disorders, and neurocognitive disorders. We also possess in-depth knowledge of trial design, study operationalization, and execution. This includes developing study protocols, ensuring compliance with federal guidelines for good clinical practice, and analyzing results. This work directly supports our academic teaching and clinical missions because psychiatrists and other practitioners need to understand the process of developing new drugs from discovery to approval. Additionally, Alabamians benefit from this program’s efforts by gaining access to novel treatments for severe and complex conditions, which often leave many patients without adequate response.
Leadership
Matthew Macaluso, D.O.
Program Lead
Professor
Bee McWane Reid Chair in Mood Disorders
Vice Chair for Clinical Affairs
Clinical Director, UAB Depression and Suicide Center
macaluso@uab.edu